世界卫生组织指南关于不孕症预防、诊断和治疗的推荐意见
该指南由世界卫生组织按照指南制定手册开发,组建了30名多学科成员组成的指南制定组,采用GRADE方法评估证据确定性。指南针对不孕症预防、诊断和治疗提出40条推荐和6条良好实践声明,多数推荐为条件性推荐,因相关证据缺乏或确定性低或极低。
要点
- 指南提出40条推荐和6条良好实践声明,涵盖不孕症预防、诊断和治疗。
- 多数推荐为条件性推荐,因相关证据缺乏或确定性低或极低。
- 指南未对男性抗氧化补充剂的使用作出推荐或反对推荐。
核心结论
- 世界卫生组织针对不孕症预防、诊断和治疗制定了40条推荐和6条良好实践声明。
- 指南以公平、科学和将生育保健纳入全民健康覆盖为核心,旨在支持各国提供高质量、公平且有效的医疗保健。
研究设计与样本
- 指南依据世界卫生组织指南制定手册制定,组建了包括临床医生、政策制定者、研究人员、实施者和患者团体代表在内的30名多学科、地域多样化指南制定组。
- 开展了新的系统评价或更新了现有系统评价,采用GRADE方法评估证据确定性并指导推荐意见的形成。
- 推荐意见由30名成员组成的外部评审组审查,并经世界卫生组织批准。
主要发现
- 指南提出6条关于不孕症一般管理的良好实践声明,涉及检查选择、倾听不孕个体和夫妇、选择治疗决策、临床随访和记录治疗结局。
- 预防方面,指南提供关于提供生育和不孕信息(1条)、减少性传播感染导致的不孕风险(1条)、生活方式因素(1条)和烟草使用(1条)的推荐。
- 诊断方面,指南提供关于女性排卵功能障碍(3条)、输卵管疾病(1条)或宫腔异常(5条)所致不孕的诊断推荐,男性精液检查重复时机(2条)的推荐,以及不明原因不孕的诊断推荐(1条)。
- 治疗方面,指南提供关于多囊卵巢综合征(6条)、输卵管疾病(5条)、子宫纵隔(1条)、精索静脉曲张(4条)和不明原因不孕(6条)治疗的推荐。
- 基于现有证据,指南制定组未对男性使用抗氧化补充剂作出推荐或反对推荐。
关键数值与推荐
- 指南制定组未对男性使用抗氧化补充剂作出推荐或反对推荐。
临床怎么用
- 指南主要供医疗保健专业人员使用,同时也是政策制定者制定国家指南的重要来源,并为患者支持组织、倡导组织、资助和慈善机构、民间社会、专业学会和其他非政府组织提供信息。
- 指南的推荐未覆盖不孕症和生育保健的所有方面,后续版本将扩大推荐范围。
局限性
- 多数推荐为条件性推荐,因为相关证据缺乏或确定性低或极低。
- 指南识别了关键研究空白。
- 指南的推荐未覆盖不孕症和生育保健的所有方面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The field of sexual and reproductive health care, including family planning has progressed in the last several decades. Significant progress has also been made in the field of medically assisted reproduction. Globally one in six people experience infertility in their lifetime. However, many countries do not include the prevention, diagnosis, and treatment of infertility in health policies, financing and services, and many do not have national clinical guidelines for the prevention, diagnosis and treatment of infertility. OBJECTIVE: To determine what interventions are recommended for prevention, diagnosis and treatment of infertility among individuals and couples. DESIGN, SETTING: The guideline was developed according to the WHO handbook for guideline development. A Guideline Development Group (GDG) was assembled and included a multidisciplinary and regionally diverse set of clinicians, policymakers, researchers, implementers and representatives of patient groups (n=30). The GDG prioritised key recommendation questions to address in the guideline. New systematic reviews were conducted, or existing reviews updated, to inform the recommendations. The GRADE approach was used to assess the certainty of the evidence and to guide the formulation of recommendations. MAIN OUTCOME MEASURES: The GDG interpreted evidence and made judgments about the balance between benefits and harms (including patients' values) as well as costs, feasibility, acceptability, and equity. The recommendations were drafted, reviewed by an External Review Group (ERG) comprising 30 members, and approved by the WHO. RESULTS: The guideline makes good practice statements related to the general management of infertility (n=6) including (i) selection of tests, (ii) listening to individuals and couples with infertility, (iii) choosing treatment decisions, (iv) clinical follow-up, and (v) documenting outcomes of treatment. In relation to prevention, it provides recommendations related to the provision of information about fertility and infertility (n=1) and reduction of infertility risk from sexually transmitted infections (STIs; n=1), lifestyle factors (n=1), and tobacco use (n=1). In terms of diagnosis, recommendations for diagnosing infertility caused by ovulatory dysfunction (n=3), tubal disease (n=1), or uterine cavity abnormalities (n=5) among females are provided. For males, the guideline provides recommendations regarding when a semen test should be repeated (n=2). Also included is a recommendation for diagnosing unexplained infertility (n=1). Regarding treatment, the guideline provides recommendations related to the treatment of polycystic ovary syndrome (PCOS, n=6), tubal disease (n=5), uterine septae (n=1), varicocele (n=4), and unexplained infertility (n=6). Based on available evidence, the GDG did not make a recommendation for or against the use of antioxidant supplements in males. Most recommendations were conditional because relevant evidence was either absent, or of low or very low certainty. Critical research gaps were identified. CONCLUSIONS: The World Health Organization (WHO) made 40 recommendations and six good practice statements for the prevention, diagnosis and treatment of infertility. By centring equity, science, and the imperative to provide fertility care as part of universal health coverage, the guideline aims to support countries in delivering high-quality, equitable, and effective healthcare for all. Although the guideline is primarily intended for use by health care professionals, it is an important source for policymakers to inform national guidelines and to inform the work of professional patient support, including advocacy organizations, funding and philanthropic agencies, civil society, professional societies and other nongovernmental organizations that provide social, financial and technical support to reproductive health programmes. The recommendations do not cover all aspects of infertility and fertility care, but subsequent editions of the guideline will expand the scope of recommendations.
引用
- Mburu G, Santesso N, Brignardello-Petersen R, et al. Recommendations from the WHO guideline for the prevention, diagnosis, and treatment of infertility. Fertil Steril. 2025. PMID: 41387135. doi:10.1016/j.fertnstert.2025.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。